134997-91-4

Usage

Molecular Structure

A heterocyclic compound with a six-membered ring containing oxygen, nitrogen, and carbon atoms, with a ketone group attached to the ring and an acetic acid group attached to the carbon chain.

+ Presence of a ketone group

Suggests potential medicinal properties due to its ability to act as a reactive site in biological systems.

+ Derivative of benzoxazin

Indicates that the compound may have similar properties or potential pharmaceutical applications as its parent compound.

Potential Applications

+ Research on 2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-6-YL)ACETIC ACID may lead to the development of new drugs or therapeutic agents for various diseases and conditions.

Upstream product

• 10463-20-4 4-hydroxy-3-nitrophenylacetic acid 
• 1455471-90-5 ethyl 2-(4-(2-methoxy-2-oxoethyl)-2-nitrophenoxy)acetate 
• 866038-49-5 methyl 2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acetate 
• 156-38-7 4-hydroxyphenylacetate 
• 104-01-8 4-Methoxyphenylacetic acid 
• 61873-93-6 methyl (4-hydroxy-3-nitrophenyl)acetate 
• 34837-88-2 methyl 2-(4-methoxy-3-nitrophenyl)acetate 
• 23786-14-3 4-methoxy-phenyl acetic acid methyl ester 

Relevant academic research and scientific papers

N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES

The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl] (phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.

SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS

The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.